Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DRINN: Exenatide for Cognitive Decline in Prediabetic MCI Patients
NCT02847403Phase 3Unknown
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma
- Start
- Feb 2016
- Primary completion
- Jul 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of exenatide in Mild Cognitive Impairment (MCI), sponsored by Azienda Ospedaliero-Universitaria di Parma. Status: unknown.
02
Drugs
exenatide
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT02847403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02847403.